Theravance Biopharma, Mylan Ireland and Mylan Specialty have entered into a settlement agreement with Teva Pharmaceutical Industries over their Yupelri inhalation drug, according to a Securities and Exchange Commission filing.
The biopharmaceutical company on Monday said the parties agreed to grant Teva a royalty-free, non-exclusive, non-transferable license to manufacture and market Teva's generic version of Yupelri in the U.S. on or after the licensed launch date of April 23, 2039.
The settlement is subject to review by the Justice Department and the Federal Trade Commission.
The companies didn't disclose financial details on the settlement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.